860 related articles for article (PubMed ID: 2428480)
1. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
2. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
Fuyama S; Yamamoto H; Arai S
Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
4. Effector mechanisms of syngeneic anti-tumour responses in mice. I. Establishment and characterization of an exogenous IL-2-independent cytotoxic T-lymphocyte line specific for radiation-induced leukaemia RL male 1.
Kuribayashi K; Keyaki A; Sakaguchi S; Masuda T
Immunology; 1985 Sep; 56(1):127-40. PubMed ID: 3876271
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
7. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.
Keyaki A; Kuribayashi K; Sakaguchi S; Masuda T; Yamashita J; Handa H; Nakayama E
Immunology; 1985 Sep; 56(1):141-51. PubMed ID: 3876272
[TBL] [Abstract][Full Text] [Related]
8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
10. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
11. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
Lee FH; Currie D; Hwang KM
Cancer Res; 1984 Dec; 44(12 Pt 1):5491-8. PubMed ID: 6208997
[TBL] [Abstract][Full Text] [Related]
13. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
[TBL] [Abstract][Full Text] [Related]
14. [Effects of adult thymectomy on the growth of 203-glioma in mice--analysis of T cell subpopulation in tumor immunology].
Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
No To Shinkei; 1982 Nov; 34(11):1067-75. PubMed ID: 6984337
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
16. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
Fuyama S; Komatsu H; Arai S
Cell Immunol; 1991 Oct; 137(1):200-15. PubMed ID: 1679379
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
19. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]